IGMS
IGM Biosciences, Inc.
6.56
USD
This page is just a preview of the data found in TrendSpider’s full version
IGM Biosciences, Inc. stock is up 45.45% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 December’s closed higher than November. 40% of analysts rate it a buy.
IGM Biosciences, Inc. develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma.
